Hydrocodone

Aleve® Speaks The Painful Truth, Encouraging Consumers to Explore Their Pain Management Options

Retrieved on: 
Monday, March 25, 2024
Biotechnology, Health, Science, Pharmaceutical, Research, Aromatherapy, National Consumers League, Hydrocodone, MAPDA, NCL, Partnership, Mother, Education, Patient, Yoga, Paracetamol, Opioid use disorder, Naproxen, Trial of the century, Bayer, Meditation, OTC, CDC, Love, Pain, Multimedia, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20240325938118/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240325938118/en/
    Aleve launches "The Painful Truth" campaign with Mothers Against Prescription Drug Abuse (MAPDA) and National Consumers League (NCL).
  • (Photo: Business Wire)
    While opioid dispensing rates in the U.S. are slowly ticking down, they remain elevated compared with rates in other countries.
  • “The Painful Truth” campaign launches with a three-minute film featuring real pain sufferers who are at crossroads in their pain relief journeys and seeking guidance.
  • At this critical juncture in their care, the patients are encouraged to consider different pain relief options.

Ibogaine By David Dardashti Analyzes Connections Between Physical and Emotional Pain

Retrieved on: 
Monday, January 15, 2024
Hydrocodone, Oxycodone, Fentanyl, Physical fitness, Communication, Opioid, Chronic pain, Ibogaine, Pain, Methadone, Buprenorphine/naloxone, Research, Brain, Nursing

While opiates are commonly used to treat physical pain, they have been found to have a significant impact on emotional pain as well.

Key Points: 
  • While opiates are commonly used to treat physical pain, they have been found to have a significant impact on emotional pain as well.
  • Research suggests that opiates enhance the production of opiate receptors, creating interconnected pathways that regulate both physical and emotional pain.
  • These drugs create interconnected pathways that regulate both emotional and physical pain, providing relief to individuals struggling with opioid addiction.
  • This not only helps individuals recover without having to undergo physical and emotional discomfort, but also stabilizes the brain and body, improving communication between physical and emotional pain.

CVS Health completes rollout of time delay safes in Florida

Retrieved on: 
Tuesday, April 18, 2023
Discovery, Inc., Pharmacy, Parent, Law enforcement, Oxycodone, CVS, Health, CVS Pharmacy, Water supply, Thought, Pharmacist, School, Student, CVS Health, News, NYSE, Hydrocodone, Safety, Personal care, Drug, Pharmaceutical industry, Target, Knowledge

WOONSOCKET, R.I., April 18, 2023 /PRNewswire/ -- As part of an ongoing commitment to support law enforcement and build safer communities, CVS Health® (NYSE: CVS) today announced the installation of time delay safe technology in all 838 CVS Pharmacy locations throughout Florida, including those in Target stores.

Key Points: 
  • In addition, the safes help improve the safety and well-being of CVS Pharmacy customers and employees.
  • Thank you for helping to safeguard your CVS Pharmacy stores to strengthen safety at retail pharmacies in Florida," said Scott Shalley, CEO of Florida Retail Federation.
  • CVS Health first implemented time delay safe technology in 2015 in CVS Pharmacy locations across Indianapolis, a city experiencing a high volume of pharmacy robberies at the time.
  • The CVS Health time delay safe program is among many company initiatives to address and prevent prescription medication misuse and diversion.

Global Naloxone Market Report 2022 to 2030: Parenteral Segment Dominated the Formulation Market - ResearchAndMarkets.com

Retrieved on: 
Monday, January 30, 2023
Health, Pharmaceutical, Heroin, Drug, Drug overdose, Opioid overdose, Oxycodone, Buprenorphine, Fentanyl, Incidence, Morphine, Death, Growth, Opioid, Injection, Prevalence, Hydrocodone, Hospital, Speciality chemicals, Marketing, Renewable energy, Naloxone, Buprenorphine/naloxone

The global naloxone market is expected to grow at a CAGR of 10.1% during the forecast period of 2022-2030.

Key Points: 
  • The global naloxone market is expected to grow at a CAGR of 10.1% during the forecast period of 2022-2030.
  • The increasing prevalence of opioid overdoses is expected to drive the growth of the naloxone market.
  • An increasing incidence of opioid drug abuse in both the developed and developing worlds remains the key driver for the market growth of the naloxone market.
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Naloxone market worldwide?

KemPharm Announces Appointment of Christopher Posner as New Independent Director

Retrieved on: 
Tuesday, November 29, 2022
Marketing, KMPH, Regulation of tobacco by the U.S. Food and Drug Administration, NPC, EAP, Security (finance), Neurodegeneration, Organization, Economics, LEO, Pfizer, Policy, Patient, Market Access Program, Hydrocodone, NDA, Investigational New Drug, Paracetamol, Fuqua School, Niemann–Pick disease, New Drug Application, FDA, SDX, Food, Narcolepsy, Idiopathic hypersomnia, Glycogen storage disease, Duke University, Clinical trial, ADHD, Triple accreditation, Bristol Myers Squibb, Benzhydrocodone, Villanova University, Central nervous system, CNS, Leo Pharma, Endo International, IH, Business, Pharmaceutical industry

CELEBRATION, Fla., Nov. 29, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a biotechnology company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS) and neurodegenerative diseases, lysosomal storage disorders and related treatment areas, today announced the appointment of Christopher Posner to serve on the Company’s Board of Directors.

Key Points: 
  • Mr. Posner is currently the president and CEO of Cara Therapeutics (Nasdaq: CARA), a commercial-stage biopharmaceutical company.
  • He brings more than 20 years of global pharmaceutical experience to KemPharm, including expertise in preparing and executing commercial product launches.
  • Prior to joining Cara Therapeutics, Mr. Posner was President and Chief Executive Officer of LEO Pharma, Inc., the U.S. subsidiary of LEO Pharma A/S.
  • I welcome the opportunity to join KemPharm at a very exciting period for the company, said Mr. Posner.

KemPharm Receives FDA Orphan Drug Designation for Serdexmethylphenidate (SDX) for the Treatment of Idiopathic Hypersomnia (IH)

Retrieved on: 
Friday, November 18, 2022
Sleep disorder, KMPH, API, SDX, Food, Compte rendu, ADHD, Narcolepsy, Idiopathic hypersomnia, Policy, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Somnolence, NPC, Orphan drug, Special access program, Benzhydrocodone, Central nervous system, Disease, CNS, EAP, Hydrocodone, Security (finance), Neurodegeneration, NDA, Sleep, Research, IH, Glycogen storage disease, Paracetamol, Niemann–Pick disease, Clinical trial, FDA, Pharmaceutical industry

CELEBRATION, Fla., Nov. 18, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a biotechnology company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS) and neurodegenerative diseases, lysosomal storage disorders and related treatment areas, today announced that the U.S. Food and Drug Administration (FDA) has granted the Orphan Drug Designation to serdexmethylphenidate (SDX), KemPharm’s proprietary prodrug of d-methylphenidate (d-MPH), for the treatment of idiopathic hypersomnia (IH), a rare neurological sleep disorder.

Key Points: 
  • SDX is the sole active pharmaceutical ingredient (API) in KP1077, KemPharms lead clinical candidate being developed as a treatment for IH and narcolepsy.
  • We appreciate the FDAs decision to grant Orphan Drug Designation to SDX for IH, a rare sleep disorder characterized by multiple, debilitating symptoms for which few treatment options exist, stated Travis Mickle, Ph.D., President and Chief Executive Officer of KemPharm.
  • Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same disease or condition, or the same drug for a different disease or condition.
  • Among the other benefits of Orphan Drug Designation are tax credits for certain research and a waiver of the NDA application user fee.

Global Opioid Use Disorder Market Report to 2031 - Featuring Alkermes, AstraZeneca, BioDelivery Sciences International and Camurus Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 10, 2022
Health, Pharmaceutical, Codeine, Drug, OUD, Cardiovascular disease, Methadone, Fentanyl, Age, Opioid use disorder, Breast, Conditional sentence, Knee, Injection, Lung cancer, Incidence, Population, Buprenorphine, Porter's five forces analysis, Oxycodone, Neurological disorder, Cancer, World Cancer Research Fund International, Morphine, Joint, Self-control, Benchmarking, Distribution, Journal, Motivation, Patient, Pain, Breast cancer, Growth, Administration, Hydrocodone, JAMA Network Open, The New England Journal of Medicine, Opioid, Route of administration, Injury, CAGR, Pharmaceutical industry, Cereal, Dentistry, Retail

Opioid usage disorder (OUD) is a chronic, relapsing brain disorder that is characterized by obsessive opioid seeking and use despite negative effects.

Key Points: 
  • Opioid usage disorder (OUD) is a chronic, relapsing brain disorder that is characterized by obsessive opioid seeking and use despite negative effects.
  • Opioid use disorder consists of an overpowering desire to use opioids, increased opioid tolerance, and withdrawal syndrome when discontinued.
  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the opioid use disorder market analysis from 2021 to 2031 to identify the prevailing opioid use disorder market opportunities.
  • The report includes the analysis of the regional as well as global opioid use disorder market trends, key players, market segments, application areas, and market growth strategies.

KemPharm to Report Third Quarter 2022 Financial Results

Retrieved on: 
Tuesday, November 1, 2022
IH, Idiopathic hypersomnia, Benzhydrocodone, ADHD, Policy, YouTube, GLOBE, Paracetamol, NPC, KMPH, Program, Degenerative disease, Market Access Program, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Hydrocodone, EAP, Narcolepsy, NDA, Company, Investor relations, FDA, Patient, Food, Webcast, SDX, Nasdaq, Niemann–Pick disease, Pharmaceutical industry

ET, to discuss its corporate and financial results for the third quarter 2022.

Key Points: 
  • ET, to discuss its corporate and financial results for the third quarter 2022.
  • The audio webcast with slide presentation will be accessible via the Investor Relations section of the Companys website, http://investors.kempharm.com/ .
  • An archive of the webcast and presentation will be available for 90 days beginning at approximately 6:00 p.m.
  • KemPharm has a diverse product portfolio, combining a clinical-stage development pipeline with NDA-stage and commercial assets.

KemPharm Supports Niemann-Pick Awareness Month During October and Global Niemann-Pick Awareness Day on October 19th

Retrieved on: 
Tuesday, October 4, 2022
Degenerative disease, YouTube, Paracetamol, GLOBE, Facebook, NNPDF, Idiopathic hypersomnia, Death, EAP, LinkedIn, IND, Disease, Niemann–Pick disease, Food, Clinical trial, SDX, Private Securities Litigation Reform Act, Twitter, NPC, Cognition, FDA, NDA, KMPH, Education, Benzhydrocodone, Awareness, Caregiver, Narcolepsy, Nasdaq, Speech, ADHD, U.S. Securities and Exchange Commission, Policy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Program, IH, Security (finance), Patient, Compte rendu, Forward-looking statement, Diagnosis, Neurodegeneration, Special access program, Organization, Hydrocodone, Company, Senior, Pharmaceutical industry

CELEBRATION, Fla., Oct. 04, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc.(NasdaqGS: KMPH) (KemPharm, or the Company), a biotechnology company focused on the discovery, development and commercialization of novel treatments for rare diseases, announced its support for Niemann-Pick Awareness Month, which is the month of October, and Global Niemann-Pick Awareness Day, which is October 19th.

Key Points: 
  • CELEBRATION, Fla., Oct. 04, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc.(NasdaqGS: KMPH) (KemPharm, or the Company), a biotechnology company focused on the discovery, development and commercialization of novel treatments for rare diseases, announced its support for Niemann-Pick Awareness Month, which is the month of October, and Global Niemann-Pick Awareness Day, which is October 19th.
  • KemPharm supports and unites with these groups in advocating for those affected by NPC and their families and in seeking new therapeutic options for NPC where no satisfactory alternative treatments currently exist.
  • KemPharm is a biotechnology company focused on the discovery, development and commercialization of novel treatments for rare diseases.
  • KemPharm has a diverse product portfolio, combining a clinical-stage development pipeline with NDA-stage and commercial assets.

KemPharm Announces Positive Topline Data from Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX)

Retrieved on: 
Wednesday, September 28, 2022
YouTube, Central nervous system, Volunteering, Hydrocodone, Nasdaq, Policy, Twitter, Sleep disorder, FDA, Food, Narcolepsy, LinkedIn, Company, KMPH, NPC, Cmax, Private Securities Litigation Reform Act, NDA, ADHD, Forward-looking statement, Idiopathic hypersomnia, Paracetamol, U.S. Securities and Exchange Commission, Program, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Facebook, Methylphenidate, Clinical trial, Special access program, Glycogen storage disease, SDX, Compte rendu, Heart rate, API, IH, Niemann–Pick disease, CNS, EAP, Security (finance), Pharmacokinetics, GLOBE, Plasma, Benzhydrocodone, Pharmaceutical industry, Generic drug

CELEBRATION, Fla., Sept. 28, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS), neurodegenerative and lysosomal storage diseases, today announced topline data from its exploratory Phase 1 clinical trial confirming the relative cardiovascular effects and pharmacokinetics of serdexmethylphenidate (SDX) compared to immediate-release and long-acting formulations of Ritalin® (racemic methylphenidate), a commonly prescribed CNS stimulant. SDX, KemPharm’s proprietary prodrug of d-methylphenidate (d-MPH), is the sole active pharmaceutical ingredient (API) in KP1077, a potential treatment for idiopathic hypersomnia (IH), a rare sleep disorder.

Key Points: 
  • KemPharm expects to initiate a Phase 2 clinical trial of KP1077 in patients with IH prior to year-end 2022 and a second trial in patients with narcolepsy in 2023.
  • We are pleased with the initial results from the Phase 1 cardiovascular safety trial of SDX, which demonstrated the potential for higher dose formulations of SDX to be safe and well-tolerated.
  • Overall, the data suggest that SDX can be safely dosed at levels higher than current products, which is expected to result in improved efficacy.
  • Maximal plasma concentrations (Cmax) of d-MPH were similar for both Ritalin treatments that were administered at equal doses of 80mg.